TX-SNOW-SOFTWARE
10.11.2022 15:01:39 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today announced new and enhanced capabilities to support IT leaders seeking to negotiate better contract terms, lower operating expenses and boost organizational-wide efficiencies during this period of macroeconomic uncertainty. The latest features offer a richer view of an organization’s IT investments and the impact to the business, providing new ways to optimize costs and ensure value of complex technologies like containers and cloud services. Container visibility, one of the newest innovations on the Snow Atlas platform, provides details on applications running in Kubernetes containers to identify cost savings.
“The macroeconomic environment is forcing organizations to seek a deeper understanding of how all areas of their business are performing,” said Sanjay Castelino, Chief Product and Customer Officer at Snow. “With large annual budgets devoted to IT spend, demonstrating return on investment for every technology purchase is vital for CIOs and IT teams. The latest release from Snow not only identifies how technology is used but also offers use cases to support more sustainable IT practices such as understanding the carbon footprint of devices. With IT environments more complex than ever, the intelligence Snow provides serves as the backbone for organizations seeking to get more control over IT spending and risk.”
Gaining Visibility of Container Environments
More than 70% of global organizations will use containerized applications by 2023, according to industry analysts. Widespread use of containers creates new barriers for organizations seeking to understand what is running in a container – let alone control costs.
The new container visibility feature available on Snow Atlas is designed to provide IT teams and IT asset managers (ITAM) details on what applications are running, how many containers are used in their environment, and how long containers have been running. In this release, the capability provides insights into Microsoft, Oracle and Red Hat standard containerized applications running in Kubernetes environments. Container visibility is available for Kubernetes environments running on major cloud services such as Amazon Web Services (AWS) and Microsoft Azure environments. This insight enables IT and ITAM teams to manage cost more efficiently.
Snow is inviting organizations with Kubernetes environments to use the functionality, with general availability of the capability aimed at early 2023.
Empowering ITAM to Partner with FinOps to Manage Rising Cloud Costs
To give a more complete picture of the end-to-end organizational tech stack, the latest release from Snow gives ITAM teams a spend snapshot across AWS and Azure in the terminology and views used by ITAM. With this new service – available to all Snow Atlas customers – ITAM teams have improved views of their organization’s spend profile in public cloud natively within their SAM tool. By building this feature natively within the existing SAM product, Snow makes it easier for ITAM to drive conversations about spend optimization with cloud stakeholders and FinOps teams.
For organizations with more mature cloud practices, FinOps or cloud operations practitioners, Snow Cloud Cost powered by Anodot provides greater depth of visibility, insights and analysis on public cloud spend, controls for budget management and spend allocation, detection of anomalies and recommendations for optimizing spend.
Enabling IT to Build a Sustainable Enterprise
Developing a more sustainable enterprise is a top priority for most CIOs. Snow makes it easier for IT teams to deliver on their sustainability goals. Organizations can leverage existing ITAM data, such as the laptop and desktop details, to assess their sustainability baseline. This sustainability intelligence report from Snow also includes curated information on how many certified sustainable devices exist, the spectrum of energy efficient devices and an evaluation of carbon emission reduction with on-premises to cloud shifts. The data provided by Snow enables CIOs and IT leaders to take proactive measures to actively manage and advance their sustainability initiatives.
Expanded Support to Reduce S/4HANA Migration Risks
With the end of maintenance for Business Suite 7 approaching, the migration to S/4HANA is a strategic imperative for many organizations. Snow is releasing new license intelligence, contract management and management dashboards for Snow Optimizer for SAP® Software to help offer further support with S/4HANA migrations. The new license intelligence capabilities allow organizations to easily simulate alternative license scenarios for both usage and authorization-based licensing, helping them decide on the most efficient and cost-effective migration strategy. In addition, new functionality allows for more transparent and secure management of an organization’s SAP environment by providing insight into license metrics and enhanced controls over contract management.
These new and enhanced capabilities follow several notable product milestones for Snow this year, including a new host of capabilities for Snow Atlas, a new partnership with Anodot to transform cloud cost management, verification on Oracle Database and Database Options and new enhancements for Snow Commander.
For more information or to request a demo, please visit www.snowsoftware.com.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005344/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
